pyridostigmine bromide

Myasthenia gravis

0.3–1.2 g per day in divided doses

Molecular weight :261.1

%Protein binding :No data

%Excreted unchanged in urine : 80–90

Volume of distribution (L/kg) :0.8–1.4

half-life – normal/ESRD (hrs) :3–4/6

20–30 35% of daily dose

10 to 20 : 35% of daily dose

<10 : 20% of daily dose

CAPD :Unknown dialysability. Dose as in GFR <10 mL/min

HD :Unknown dialysability. Dose as in GFR <10 mL/min

HDF/high flux :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD :Unknown dialysability. Dose as in GFR 10 to 20 mL/min

Potentially hazardous interactions with other drugsAminoglycosides, clindamycin and polymyxins antagonise effects of pyridostigmine

–

Oral

–

–